StockNews.AI
OCX
StockNews.AI
154 days

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

1. Oncocyte Corp. will report Q4 2024 financial results on March 24. 2. A live webinar will occur on the same day for financial discussion. 3. Oncocyte specializes in diagnostic technologies for organ transplantation and cancer. 4. Their products, including VitaGraft and DetermaIO, enhance patient care. 5. A replay of the earnings call will be accessible post-event.

3m saved
Insight
Article

FAQ

Why Bullish?

The upcoming earnings report and webinar suggest positive business engagement, which historically can boost stock performance.

How important is it?

The information regarding earnings and forthcoming product discussions is likely to directly influence investor decisions.

Why Short Term?

Investor sentiment may improve shortly before the earnings report, akin to past earnings season outcomes.

Related Companies

GRAILEXASUTCCLDX
IRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q4 2024 Earnings Webinar. An archived replay will be available after the call concludes on Oncocyte’s investor relations website at https://investors.oncocyte.com. About OncocyteOncocyte is a leading diagnostics technology company. The company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages: VitaGraft Kidney™ - https://oncocyte.com/vitagraft-kidney/VitaGraft Liver™ - https://oncocyte.com/vitagraft-liver/GraftAssure™ - https://oncocyte.com/graftassure/DetermaIO™ - https://oncocyte.com/determa-io/DetermaCNI™ - https://oncocyte.com/determa-cni/ VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation. CONTACT:Jeff RamsonPCG Advisory(646) 863-6893jramson@pcgadvisory.com

Related News